跳转到主要内容


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
快速连接

依度沙班

依度沙班 API

依度沙班-API

CAS Number: 480449-70-5

治疗类别
心血管的
API技术
合成
剂型
Oral Solid/Tablets
瑞迪博士研发状态
正在开发中
创新品牌(美国)
Savaysa

作用机制

Edoxaban is a direct oral anticoagulant (DOAC) that acts as a factor Xa inhibitor. It works by blocking the activity of factor Xa, a key component of the coagulation cascade.

Factor Xa plays a central role in the blood coagulation process, converting prothrombin to thrombin and leading to the formation of a blood clot. By inhibiting the activity of factor Xa, edoxaban helps to reduce the formation of blood clots and the risk of thromboembolic events such as stroke and deep vein thrombosis (DVT).

Edoxaban works differently from traditional anticoagulants such as warfarin, which work by blocking the recycling of vitamin K and the synthesis of coagulation factors. Unlike warfarin, edoxaban does not require frequent monitoring or dose adjustments and has a more predictable anticoagulant effect.

Overall, the mechanism of action of edoxaban involves the inhibition of factor Xa, leading to a reduction in the formation of blood clots and the risk of thromboembolic events.

适应症

Edoxaban is FDA-approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). It is also indicated for the treatment and reduction of risk of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Atrial Fibrillation: Edoxaban is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation who have one or more risk factors, such as age, congestive heart failure, hypertension, or previous stroke or transient ischemic attack (TIA).

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): Edoxaban is indicated for the treatment of DVT and PE, and for the reduction of the risk of recurrent DVT and PE following initial treatment with a parenteral anticoagulant.

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴,是全球领先的活性药物成分(API)供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API(如类固醇,多肽,复杂长链分子和高效API(HPAPI /肿瘤药物))方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准,从而为这一专业知识提供补充。 Dr. Reddy's博士 依度沙班 API是研发,知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量,安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化,从而避免短缺并满足需求的突然激增。

Cardiovascular API Products:

Learn More

联系我们

请填写以下表格,我们会尽快与您联系

给我们发电子邮件: api@drreddys.com | +91 40 49002222

如果您有任何特定于国家的要求,我们将为您提供帮助。

免责声明

本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。